efficacy of glp 1 receptor agonists Safety and a GLP-1 and glucagon dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial Changes in weight with glucagon-like
Description
Inhibition of glucagon secretion
Weight loss surgery may be the most effective treatment for morbid obesity, but we need less radical choices, such as drugs (134)
Back Wei, Y, Mojsov, S (1995) 'Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences', FEBS Letters , 368, 219-24
GLP-1 increased cAMP but did not affect amylase secretion
Thus, the different volume regulation by SGLT2-I may limit the aberrant neurohumoral and RAAS stimulation that occurs in the setting of volume depletion (54, 55)
